Oncology News

In the era of direct-acting antivirals, rates of hepatocellular carcinoma are rising in patients without cirrhosis, particularly Black patients, according to a presentation at The Liver Meeting Digital Experience.

Healio Gastroenterology and Hepatology presents the following report on highlights from The Liver Meeting Digital Experience.

The FDA granted orphan drug designation to rivoceranib for the treatment of hepatocellular carcinoma.

Use of a transforming growth factor-beta pathway-based combinatorial serum protein panel may aid in the early detection of hepatocellular carcinoma, according to research presented at The Liver Meeting Digital Experience.

LAS VEGAS – In this video exclusive, Nancy S. Reau, MD, FAASLD, AGAF, discussed the Liver Health Annual Trends Report, which was launched during a panel discussion hosted by Salix Pharmaceuticals at the ACG Annual Scientific Meeting.

LAS VEGAS – In this video exclusive, Donna Cryer, JD, founder, president and CEO Global Liver Institute, spoke on the launch of the Liver Health Annual Trends Report and its possible impact for patients with chronic liver disease.

LAS VEGAS – In this video exclusive from the ACG Scientific Annual Meeting, Amit Singal, MD, from UT Southwestern Medical Center, discussed best practices for the screening, surveillance, and treatment of hepatocellular carcinoma.

The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Pembrolizumab prolonged OS compared with placebo for certain patients with advanced hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.

Recently the European Association for the Study of the Liver updated its clinical practice guidelines for management of hepatocellular carcinoma.